参考文献/References:
[1] Zarowitz BJ,Cheng LI,Allen C,et al. Osteoporosis prevalence
and characteristics of treated and untreated nursing home residents with osteoporosis[J]. J Am Med Dir Assoc, 2015,16(4):341-348.
[/br][2] Hassler N, Gamsjaeger S, Hofstetter B, et al. Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties[J]. Osteoporos Int, 2015,26(1):339-352.
[/br][3] Niimi R, Kono T, Nishihara A, et al. Analysis of daily teriparatide treatment for osteoporosis in men[J]. Osteoporos Int, 2015,26(4):1303-1309.
[/br][4] Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis[J]. N Engl J Med, 2003,349(13):1216-1226.
[/br][5] Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis[J]. J Clin Endocrinol Metab, 2010,95(4):1838-1845.
[/br][6] Muschitz C, Kocijan R, Fahrleitner-Pammer A, et al. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density[J]. J Bone Miner Res, 2013,28(1):196-205.
[/br][7] Cosman F, Nieves J, Woelfert L, et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women[J]. J Bone Miner Res, 1998,13(6):1051-1055.
[/br][8] Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men[J]. J Clin Endocrinol Metab, 2006,91(8):2882-2887.
[/br][9] Minne H, Audran M, Simões ME, et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study[J]. Curr Med Res Opin, 2008,24(11):3117-3128.
[/br][10] Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment[J]. J Bone Miner Res, 2008,23(10):1591-1600.
[/br][11] Hofstetter B, Gamsjaeger S, Varga F, et al. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naive or on long-term alendronate therapy[J]. Osteoporos Int, 2014,25(12):2709-2719.
[/br][12] Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent[J]. J Clin Endocrinol Metab, 2009,94(10):3772-3780.
[/br][13] Cosman F, Keaveny TM, Kopperdahl D, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene[J]. J Bone Miner Res, 2013,28(6):1328-1336.
[/br][14] Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis[J]. J Clin Endocrinol Metab, 2008,93(3):852-860.
[/br][15] Whitmarsh T, Treece GM, Gee AH, et al. Mapping bone changes at the proximal femoral cortex of postmenopausal women in response to alendronate and teriparatide alone, combined or sequentially[J]. J Bone Miner Res, 2015,30(7):1309-1318.
[/br][16] Ma YL, Zeng QQ, Chiang AY, et al. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment[J]. Bone, 2014,59:139-147.
[/br][17] Keel C, Kraenzlin ME, Kraenzlin CA, et al. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice[J]. J Bone Miner Metab, 2010,28(1):68-76.
[/br][18] Stepan JJ, Burr DB, Li J, et al. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis[J]. Osteoporos Int, 2010,21(12):2027-2036.
[/br][19] Krause M, Soltau M, Zimmermann EA, et al. Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae[J]. Eur Cell Mater, 2014,28:152-163; discussion 163-165.
[/br][20] Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate[J]. J Bone Miner Res, 2009,24(12):1998-2006.
[/br][21] Misof BM, Paschalis EP, Blouin S, et al. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution(BMDD)in postmenopausal osteoporotic women previously treated with alendronate or risedronate[J]. J Bone Miner Res, 2010,25(11):2297-2303.
[/br][22] Gamsjaeger S, Buchinger B, Zoehrer R, et al. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate[J]. Bone, 2011,49(6):1160-1165.
[/br][23] Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years[J]. J Bone Miner Res, 2012,27(12):2429-2437.
[/br][24] Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate[J]. J Bone Miner Res, 2009,24(6):1110-1115.
[/br][25] Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women[J]. J Clin Endocrinol Metab, 2009,94(7):2495-2501.
[/br][26] Cosman F, Nieves JW, Zion M, et al. Daily or cyclical teriparatide treatment in women with osteoporosis on no prior therapy and women on alendronate[J]. J Clin Endocrinol Metab, 2015,100(7):2769-2776.
[/br][27] Muschitz C, Kocijan R, Fahrleitner-Pammer A, et al. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density-the CONFORS Study[J]. J Bone Miner Res, 2014,29(8):1777-1785.